Disease-focused Programs

Type 1 Diabetes

HITI's first round of pilot awards for research on Type 1 diabetes were announced on April 6, 2011. The following researchers were funded:

"Support from the HITI has
allowed new insights... which
will be useful in the future
design of CD8 Treg-mediated
immunotherapy."

Harvey Cantor

"Our studies have yielded novel
tools and reagents that facilitate
the generation of insulin producing
beta cells in the pancreas. "

Qiao Zhou and Jason Gaglia

Harvey Cantor, Dana-Farber Cancer Institute
Development of CD8-Treg-mediated Immunotherapy for Treatment of T1D.

Stephen Elledge, Harvard Medical School and Brigham and Women's Hospital
Next-Generation Display Technologies for Autoantigen Discovery in Type 1 Diabetes.

Richard Lee, Brigham and Women's Hospital, and Douglas Melton, Harvard University
Engineering Cells for Continuous Glucose Monitoring.

Towia Libermann, Beth Israel Deaconess Medical Center
Identification of Novel Biomarkers for Accurately Predicting Onset of Type 1 Diabetes.

David Mooney, Harvard University, and Kai Wucherpfennig, Dana-Farber Cancer Institute
Induction of Islet-Specific Regulatory T cells with Novel Biomaterials.

Martin Yarmush, Harvard Medical School and Massachusetts General Hospital
A Multiplex Bead-Based Assay For Early Detection Of Type I Diabetes.

Qiao Zhou, Harvard University, and Jason Gaglia, Joslin Diabetes Center
Novel Delivery System For Regenerating Beta Cells In Type I Diabetes.

These research projects were the culmination of a bold approach that used the wisdom of crowds to generate research topics. Read more and watch videos of the faculty, students, administrators, and staff who were recognized for their outstanding ideas at a celebration in September, 2010.